International and national guidelines and position papers recognizing the use of plant stanol ester for reducing LDL-cholesterol:

Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies, 2021 Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur HeartJ 2021; 42(34): 3227-3337.

The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS), 2019

Mach F, Baigent C, Catapano AL et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41(1): 111-188.4.

The Finnish Medical Society Duodecim, 2020

Vuorio A, Kovanen P, Salo M. FH-taudin (familiaalisen hyperkolesterolemian) diagnostiikka ja hoito. Helsinki: Suomalainen Lääkäriseura Duodecim, 2020. Saatavilla Internetissä: www.kaypahoito.fi/nix00310

American Diabetes Association, 2019

Standards of Medical Care in Diabetes - 2019. Cardiovascular Disease and Risk Management. Diabetes Care 2019; 42(Supp 1): S103-S123.

Polish Cardiac Society Working Group, 2018

Szymański FM, Barylski M, Cybulska B et al. Recommendation for the management of dyslipidemia in Poland — Third Declaration of Sopot. Interdisciplinary Expert Position Statement endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy. Cardiology Journal 2018; 25 (6): 655–665.

American College of Cardiology, 2017

2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol 2017; 70: 1785-1822.

American Association of Clinical Endocrinologists and American College of Endocrinology, 2017

Guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract 2017; 23 (Suppl 2): 1-87. The Finnish Medical Society Duodecim and the Finnish Cardiac Society, 2017 Eteisvärinä. Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecimin ja Suomen Kardiologisen Seuran asettama työryhmä. Helsinki: Suomalainen Lääkäriseura Duodecim, 2017. Saatavilla Internetissä: www.käypähoito.fi

Polish Cardiac Society, Polish Lipid Society and Family Medicine Aassociation, 2016 Banach M, Jankowski P, Jóźwiak J i wsp. Wytyczne PTL/KLRwP/PTK postępowania w zaburzeniach lipidowych dla lekarzy rodzinnych 2016. Lekarz POZ 4/2016.

European Atherosclerosis Society, 2015

Wiegman et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J 2015; 36: 2425-2375.

National Lipid Association, 2015

Jacobson et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 – full report. J Clin Lipidol 2015: 9(2); 129-169.

Joint British Societies, 2014

JBS 3 board: Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart 2014; 100: ii1-ii67.

European Atherosclerosis Society, 2014

Gylling H et al. Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. Atherosclerosis 2014; 232(2): 346-360.

International Atherosclerosis Society, 2014

Expert Dyslipidemia Panel. An International Atherosclerosis Society Position Paper: Global Recommendations for the Management of Dyslipidemia – full report. J Clin Lipidol 2014; 8: 29-60.

European Atherosclerosis Society, 2013

Nordestgaard BG et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Consensus statement of the European Atherosclerosis Society. Eur Heart J 2013; 34: 3478-3490.

National Heart, Lung, and Blood Institute, 2011

Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report. Pediatrics 2011; 128 (Suppl 6): S1-S44.

Joint WHO/FAO Expert Consultation, 2003

Report of a Joint WHO/FAO Expert Consultation. Diet, nutrition and the prevention of chronic diseases. WHO Technical Report Series 2003; 916: 1-149.



Visit <u>www.Benecol.co.uk/hcp</u> for more information and resources relating to plant stanol ester for healthcare professionals.

Plant stanol ester has been shown to lower cholesterol. High cholesterol is a risk factor in the development of coronary heart disease. A daily intake of 1.5–2.4 g plant stanols lowers cholesterol in 2 to 3 weeks.